Pipeline

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear.

Product Candidate
Investigational Indication
Preclinical Phase 1 Phase 2 Phase 3 Registration
OTIPRIO*
(ciprofloxacin otic suspension)
*
Acute otitis externa (“swimmer’s ear”)

86.5%

OTIPRIO*
(ciprofloxacin otic suspension)
*
Acute otitis media with tubes (AOMT)

57%

OTIVIDEX
(dexamethasone)

Ménière’s disease

74%

OTO-311
(gacyclidine)

Tinnitus

41%

Hearing Loss Programs

11%

For additional information about Otonomy’s delivery technology, click here.

*The safety and efficacy of OTIPRIO for these uses has not been established and is under clinical investigation.